Back

ORM-3819 promotes cardiac contractility on a dual mechanism of action: troponin-C dependent calcium sensitization is supported by selective PDE III inhibition

21 May 2016 (09:00 - 09:15)
Organised by:
Congress Presentation Part of: Novel drugs - how do they work? Drug therapy, other HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Doctor Laszlo Nagy

University of Debrecen, Debrecen (Hungary)

5 More presentations in this session

Presentation thumbnail
Novel drugs in heart failure: what's on the horizon?
Professor C. Maack (Wuerzburg, DE)
Slides Video
Presentation thumbnail
Effects of serelaxin on a systolic cardiac dysfunction induced by isoproterenol in mice with increased cardiac aldosterone
Doctor G. Billebeau (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Why treatment with natriuretic peptide analogs failed to fulfill our expectations? - receptor expression and function in a failing heart.
Doctor K. Kodziszewska (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Vepoloxamer (purified poloxamer-188) improves LV function, limits cardiomyocyte calcium overload and restores integrity of calciu cycling proteins in myocardium of dogs with advanced heart failure
Professor H. Sabbah (Detroit, US)
Abstract Slides Video
Presentation thumbnail
Targeting HDACs in heart failure.

Access the full session

Session thumbnail
Novel drugs - how do they work?

The Event

Event poster

HEART FAILURE 2016

21 May 2016 09:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources